Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 401–500 of 1,002
Intracellular Delivery Using Nanosecond-Laser Excitation of Large-Area Plasmonic Substrates
Saklayen, N., Huber, M., Madrid, M., Nuzzo, V., Vulis, D. I., Shen, W., Nelson, J., McClelland, A., Heisterkamp, A., & Mazur, E. (2017) · ACS Nano · doi:10.1021/acsnano.6b08162 · Cited by 82
Optogenetics in the nonhuman primate
Han, X. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-59426-6.00011-2 · Cited by 71
“Lentivectors have a modest packaging capacity of $8kb, large enough to deliver many genes of interest for gene therapy and basic research (Federico, 2003; Thomas et al., 2003).”
Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates
Galván, A., Caiola, M. J., & Albaugh, D. L. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1697-8 · Cited by 81
“On the other hand, AAVs are in many instances preferred, because, in contrast to LVs, the genetic material remains episomal and does not integrate with the host DNA, thus reducing the possibility of disrupting normal transcription (Murlidharan et al. 2014; Thomas et al. 2003).”
BackgroundHydrodynamic gene delivery in human skin using a hollow microneedle device
Dul, M., Stefanidou, M., Porta, P. A., Serve, J., O’Mahony, C., MALISSEN, B., Henri, S., Levin, Y., Kochba, E., Wong, F. S., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.028 · Cited by 81
Huang, D., Zhao, D., Wang, X., Li, C., Yang, T., Du, L., Wei, Z., Cheng, Q., Cao, H., Liang, Z., et al. (2018) · Theranostics · doi:10.7150/thno.23438 · Cited by 81
“Gene-based therapies, such as DNA vaccines [1] and tumor vaccines [2], hold great promise to treat cancers, viral infections and inherited diseases [3].”
BackgroundDifferent Methods of Delivering CRISPR/Cas9 Into Cells
Chandrasekaran, A. P., Song, M., Kim, K.-S., & Ramakrishna, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.05.001 · Cited by 81
Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain
Mastorakos, P., Zhang, C., Berry, S., Oh, Y., Lee, S., Eberhart, C. G., Woodworth, G. F., Suk, J. S., & Hanes, J. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400800 · Cited by 80
Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors
Puhl, D. L., D’Amato, A. R., & Gilbert, R. J. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.05.024 · Cited by 81
“The transgene is then cloned into the viral genome (Thomas et al., 2003).”
BackgroundCui, Z., Fan, J., Kim, S., Bezouglaia, O., Fartash, A., Wu, B. M., Aghaloo, T. L., & Lee, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.031 · Cited by 80
Shim, M. S., & Kwon, Y. J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.007 · Cited by 81
Thakker, D. R., Hoyer, D., & Cryan, J. F. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.006 · Cited by 80
Microfluidic approaches for gene delivery and gene therapy
Kim, J., Hwang, I., Britain, D., Chung, T. D., Sun, Y., & Kim, D. (2011) · Lab on a Chip · doi:10.1039/c1lc20766k · Cited by 80
Long-term Transgene Expression in the Central Nervous System Using DNA Nanoparticles
Yurek, D. M., Fletcher, A. M., Smith, G. M., Seroogy, K. B., Ziady, A. G., Molter, J., Kowalczyk, T. H., Padegimas, L., & Cooper, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.2 · Cited by 79
“001] but the main effect of time was not statistically significant [one-way ANOVA: F(2, 21) = 0.”
BackgroundMethodInfluentialMakkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
“However, viral vectors face signi fi cant limitations: immunogenicity triggering neutralizing antibodies and in fl ammation, limited packaging capacity (particularly for AAVs), complex manufacturing, and safety concerns related to insertional mutagenesis (Thomas et al., 2003; Ginn et al., 2018).”
Redundant and Synergistic Mechanisms Control the Sequestration of Blood-born Adenovirus in the Liver
Di Paolo, N. C., van Rooijen, N., & Shayakhmetov, D. M. (2009) · Molecular Therapy · doi:10.1038/mt.2008.307 · Cited by 67
Coroadinha, A. S., Schucht, R., Gama-Norton, L., Wirth, D., Häuser, H., & Carrondo, M. J. T. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.037 · Cited by 79
Ye, S., Tian, M.-M., Wang, T., Ren, L., Wang, D., Shen, L., & Shang, T. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.10.003 · Cited by 79
“Although viral vectors are highly efficient for gene therapy, their use is associated with high toxicity and immunogenicity.(3,4) Synthetic or nonviral vectors are attractive alternatives to viral vectors because of their low immunogenicity and low acute toxicity.”
BackgroundMastorakos, P., Kambhampati, S. P., Mishra, M. K., Wu, T., Song, E., Hanes, J., & Kannan, R. M. (2015) · Nanoscale · doi:10.1039/c4nr04284k · Cited by 74
Gene delivery nanoparticles to modulate angiogenesis
Kim, J., Mirando, A. C., Popel, A. S., & Green, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.003 · Cited by 79
“Different types of viruses, such as adeno-associated virus, have been employed and modified to deliver nucleic acids with high and prolonged efficacy [14].”
BackgroundNanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities
Hajipour, M. J., Mehrani, M., Abbasi, S. H., Amin, A., Kassaian, S. E., Garbern, J. C., Caracciolo, G., Zanganeh, S., Chitsazan, M., Aghaverdi, H., et al. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00323 · Cited by 80
Is Viral Vector Gene Delivery More Effective Using Biomaterials?
Wang, Y., Bruggeman, K. F., Franks, S. J., Gautam, V., Hodgetts, S. I., Harvey, A. R., Williams, R. J., & Nisbet, D. R. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001238 · Cited by 79
Yurek, D. M., Flectcher, A. M., Kowalczyk, T. H., Padegimas, L., & Cooper, M. J. (2009) · Cell Transplantation · doi:10.3727/096368909x12483162196881 · Cited by 73
Isolation of targeted AAV2 vectors from novel virus display libraries
Waterkamp, D. A., Müller, O. J., Ying, Y., Trepel, M., & Kleinschmidt, J. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.967 · Cited by 69
Mohamed, A. L., El‐Naggar, M. E., Shaheen, T. I., & Hassabo, A. G. (2015) · Microsystem Technologies · doi:10.1007/s00542-015-2776-0 · Cited by 78
Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems
Babu, A., Munshi, A., & Ramesh, R. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1313861 · Cited by 78
Use of siRNAs to prevent and treat influenza virus infection
Ge, Q., Eisen, H. N., & Chen, J. (2004) · Virus Research · doi:10.1016/j.virusres.2004.01.013 · Cited by 78
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症:英文版 · doi:10.1002/cac2.12366 · Cited by 77
“The viral vectors such as adenovirus, adeno-associated virus (AAV), and herpes virus can persist within the nucleus as extrachromosomal episomes or integrate within the host genome like lentiviruses or oncoretroviruses [78].”
BackgroundMacrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases
Singh, A. K., Talekar, M., Raikar, A., & Amiji, M. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.021 · Cited by 77
“comprehensively summarized the application of viral vectors in gene therapy along with potential challenges and associated problems [73].”
BackgroundKommareddy, S., & Amiji, M. M. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701041 · Cited by 77
Wang, Y., & Yuan, F. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-9007-2 · Cited by 78
Gene Therapy Progress and Prospects: Episomally maintained self-replicating systems
Conese, M., Auriche, C., & Ascenzioni, F. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302362 · Cited by 77
Cell-mediated enzyme prodrug cancer therapies
Mooney, R., Majid, A. A., Batalla‐Covello, J., Annala, A. J., & Aboody, K. S. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.003 · Cited by 76
Application of Non-Viral Vectors in Drug Delivery and Gene Therapy
Ren, S., Wang, M., Wang, C., Wang, Y., Sun, C., Zeng, Z., Cui, H., & Zhao, X. (2021) · Polymers · doi:10.3390/polym13193307 · Cited by 76
Microfluidic mechanoporation for cellular delivery and analysis
Chakrabarty, P., Gupta, P., Illath, K., Kar, S., Nagai, M., Tseng, F., & Santra, T. S. (2021) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100193 · Cited by 76
“Although effective for gene transfer and therapy, carrier based methods are specific to cell-types, and are often restricted by cytotoxicity, and unwanted immune, inflammatory responses, leading to lower cell viabilities [4,5,8,11].”
BackgroundCollagen scaffolds for orthopedic regenerative medicine
Cunniffe, G. M., & O’Brien, F. J. (2011) · JOM · doi:10.1007/s11837-011-0061-y · Cited by 76
Noncovalently Associated cell-penetrating Peptides for Gene Delivery Applications
Alhakamy, N. A., Nigatu, A. S., Berkland, C. J., & Ramsey, J. D. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.44 · Cited by 76
Ghosh, N., & Katare, R. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0684-1 · Cited by 76
Wang, Y., Sun, G., Gong, Y., Zhang, Y., Liang, X., & Yang, L. (2020) · Nanoscale Research Letters · doi:10.1186/s11671-020-3281-7 · Cited by 76
Progress in the Use of Adeno-Associated Viral Vectors for Gene Therapy
Büning, H., Braun‐Falco, M., & Hallek, M. J. (2004) · Cells Tissues Organs · doi:10.1159/000079988 · Cited by 76
Gene therapy progress and prospects: targeted gene repair
Parekh-Olmedo, H., Ferrara, L., Brachman, E., & Kmiec, E. B. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302511 · Cited by 75
Karlsson, J., Tzeng, S. Y., Hemmati, S., Luly, K. M., Choi, O., Rui, Y., Wilson, D. R., Kozielski, K. L., Quiñones‐Hinojosa, A., & Green, J. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009768 · Cited by 73
Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina
Ding, X.-Q., Quiambao, A. B., Fitzgerald, J. B., Cooper, M. J., Conley, S. M., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007410 · Cited by 71
“Additionally, broad application of traditional viral gene delivery can be hindered by limitations in the size of the expression cassette to be transferred, host immunity to repeat infections, and the possibility of insertional mutagenesis [10,11].”
BackgroundChen, C., Jones, C. H., Mistriotis, P., Yu, Y., Ma, X., Ravikrishnan, A., Jiang, M., Andreadis, S. T., Pfeifer, B. A., & Cheng, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.063 · Cited by 75
“However, there are appreciable concerns about viral vectors regarding their biosafety, cytotoxicity, immunogenicity, tumorigenicity, gene capacity, and targeting efficiency [3,4].”
BackgroundOsborn, M. J., Panoskaltsis‐Mortari, A., McElmurry, R. T., Bell, S., Vignali, D. A. A., Ryan, M. D., Wilber, A. C., McIvor, R. S., Tolar, J., & Blazar, B. R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.013 · Cited by 75
“For instance, retro- and lentiviral vectors possess packaging capacities of 8 kb and AAVs can accommodate b5 kb [25].”
BackgroundWang, Y., Ma, B., Abdeen, A. A., Chen, G., Xie, R., Saha, K., & Gong, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b09642 · Cited by 75
Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors
Kawabata, K., Sakurai, F., Yamaguchi, T., Hayakawa, T., & Mizuguchi, H. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.015 · Cited by 75
Gene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
“Compared to AAV, lentiviruses have one major advantage: a relatively larger carrying capacity (up to 8 kb) [20].”
BackgroundHasanzadeh, A., Hamblin, M. R., Kiani, J., Noori, H., Hardie, J. M., Karimi, M., & Shafiee, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101665 · Cited by 74
Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy
Mao, L., Ma, P., Luo, X., Cheng, H., Wang, Z., Ye, E., Loh, X. J., Wu, Y., & Li, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c02273 · Cited by 74
Park, H., Lee, S., Ahn, J. C., Rajendiran, J. C. B., & Arai, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87120 · Cited by 74
“4 In particular, designing efficient gene-delivery vectors with low cytotoxicity is considered a major challenge among scientists.”
Rational design of biodegradable cationic polycarbonates for gene delivery
Ong, Z. Y., Fukushima, K., Coady, D. J., Yang, Y. Y., Ee, P. L. R., & Hedrick, J. L. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.020 · Cited by 74
Nanoscale Strategies: Treatment for Peripheral Vascular Disease and Critical Limb Ischemia
Tu, C., Das, S., Baker, A. B., Zoldan, J., & Suggs, L. J. (2015) · ACS Nano · doi:10.1021/nn507269g · Cited by 74
Recent advances in polymeric materials for the delivery of RNA therapeutics
Ulkoski, D., Bak, A., Wilson, J. T., & Krishnamurthy, V. R. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1663822 · Cited by 73
Fisher, D. G., & Price, R. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01348 · Cited by 70
Luo, K., He, B., Wu, Y., Shen, Y., & Gu, Z. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.12.008 · Cited by 74
Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury
Hedley, D., Ogilvie, L. M., & Springer, C. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2247 · Cited by 73
Wei, Z., Zheng, S., Wang, R., Bu, X., Ma, H., Wu, Y., Zhu, L., Hu, Z., Liang, Z., & Li, Z. (2014) · Lab on a Chip · doi:10.1039/c4lc00800f · Cited by 73
Lyu, Z., Zhou, X., Liu, Q., Xue, H. Y., Yu, Q., & Chen, H. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201602036 · Cited by 73
Stimuli-Responsive Polymeric Nanocarriers for Efficient Gene Delivery
Li, Y., Gao, J., Zhang, C., Cao, Z., Cheng, D., Liu, J., & Shuai, X. (2017) · Topics in Current Chemistry · doi:10.1007/s41061-017-0119-6 · Cited by 74
Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma
Zamboni, C. G., Kozielski, K., Vaughan, H. J., Nakata, M. M., Kim, J., Higgins, L., Pomper, M. G., & Green, J. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.384 · Cited by 73
“Despite the fact that viruses are powerful vectors with high transfection efficacy[10], their application in the clinical setting raises important safety concerns[10-13].”
Exosomes: natural nanoparticles as bio shuttles for RNAi delivery
Darband, S. G., Mirza‐Aghazadeh‐Attari, M., Kaviani, M., Mihanfar, A., Sadighparvar, S., Yousefi, B., & Majidinia, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.001 · Cited by 73
Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine
Zhong, Z., Portela Catani, J. P., Mc Cafferty, S., Couck, L., Van Den Broeck, W., Gorlé, N., Vandenbroucke, R. E., Devriendt, B., Ulbert, S., Cnops, L., et al. (2019) · Vaccines · doi:10.3390/vaccines7030096 · Cited by 69
“Although vaccines based on viral vectors have a high potency, they have important drawbacks such as a labor-intensive large-scale production process, the possible neutralization of the viral vector by a pre-existing or induced adaptive immune response, and the risk of insertional mutagenesis when integrating vectors a…”
BackgroundNonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies
Choi, J. H., Rui, Y., Kim, J., Gorelick, N. L., Wilson, D. R., Kozielski, K., Mangraviti, A., Sankey, E. W., Brem, H., Tyler, B., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102115 · Cited by 73
Gorzkiewicz, M., Konopka, M., Janaszewska, A., Tarasenko, I. I., Sheveleva, N. N., Gajek, A., Neelov, I. M., & Klajnert‐Maculewicz, B. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103504 · Cited by 73
“In the 1990s, scientists focused on the idea of using viruses as carriers of genetic material, due to their innate mechanisms of introduction of DNA and RNA into the cells [28].”
BackgroundRole of Viral Vectors and Virion Shells in Cellular Gene Expression
Stilwell, J. L., & Samulski, R. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.007 · Cited by 67
Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs
Ru, R., Yao, Y., Yu, S., Yin, B., Xu, W., Zhao, S., Qin, L., & Chen, X. (2013) · Cell Regeneration · doi:10.1186/2045-9769-2-5 · Cited by 67
“However, some problems such as safety concerns regarding the gene-based delivery method of ZFNs and TALENs need to be addressed [8,20].”
Nonviral delivery of genetic medicine for therapeutic angiogenesis
Park, H., Yang, F., & Cho, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.005 · Cited by 72
“been identified [16].”
Micronozzle Array Enhanced Sandwich Electroporation of Embryonic Stem Cells
Fei, Z., Hu, X. T., Choi, H.-W., Wang, S., Farson, D. F., & Lee, L. J. (2009) · Analytical Chemistry · doi:10.1021/ac902041h · Cited by 72
Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies
Klymiuk, N., Seeliger, F., Bohlooly‐Y, M., Blutke, A., Rudmann, D. G., & Wolf, E. (2015) · Toxicologic Pathology · doi:10.1177/0192623315609688 · Cited by 72
“…have the potential to be recognized as an infection and therefore stimulate the immunological defense system by recognition of viral gene products, capsid proteins, foreign components of the gene editing tool package, like the Cas9, or foreign transgene products (Thomas, Ehrhardt, and Kay 2003).”
BackgroundYang, T.-C., Chang, C.-Y., Yarmishyn, A. A., Mao, Y.-S., Yang, Y.-P., Wang, M.-L., Hsu, C.-C., Yang, H.-Y., Hwang, D.-K., Chen, S.-J., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.10.037 · Cited by 70
Assembly strategy of liposome and polymer systems for siRNA delivery
Song, H., Hart, S. L., & Du, Z. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120033 · Cited by 73
“synthesis at larger scale of viral vectors, such as adeno-associated virus (AAV) and lentiviral vectors, also restricts their clinical application [7-11].”
BackgroundGeng, J., Xia, X., Teng, L., Wang, L., Chen, L., Guo, X., Belingon, B., Li, J., Feng, X., Li, X., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.032 · Cited by 71
Tang, C., Russell, P. J., Martiniello‐Wilks, R., Rasko, J. E. J., & Khatri, A. (2010) · Stem Cells · doi:10.1002/stem.473 · Cited by 71
Adult stem cells and tissue engineering strategies for salivary gland regeneration: a review
Yoo, C., Vines, J. B., Alexander, G. C., Murdock, K., Hwang, P. T. J., & Jun, H. (2014) · Biomaterials Research · doi:10.1186/2055-7124-18-9 · Cited by 71
“Viral vectors are currently the most efficient vectors for gene transfer, but there are some safety concerns when using viral vectors; the risk of generating insertional mutagenesis, replication-competent virus, and immune responses may limit the clinical use of viral vectors [61-63].”
BackgroundGene Transfection of Mammalian Cells Using Membrane Sandwich Electroporation
Fei, Z., Wang, S., Xie, Y., Henslee, B. E., Koh, C. G., & Lee, L. J. (2007) · Analytical Chemistry · doi:10.1021/ac070482y · Cited by 71
New Insights into Cell Culture Technology
(2017) · InTech eBooks · doi:10.5772/62590 · Cited by 65
Current Progress of Virus-mimicking Nanocarriers for Drug Delivery
Somiya, M., Liu, Q., & Kuroda, S. (2017) · Nanotheranostics · doi:10.7150/ntno.21723 · Cited by 71
“Several clinical trials failed due to the safety problem of viral vectors [17].”
BackgroundLevingstone, T. J., Herbaj, S., Redmond, J., McCarthy, H. O., & Dunne, N. (2020) · Nanomaterials · doi:10.3390/nano10010146 · Cited by 71
“Immunogenicity also poses a significant barrier because viral vectors have the potential to provoke a robust immune response post administration in vivo, resulting in the need for vector modification to overcome such complications [86].”
BackgroundCRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 70
Yao, L., Daly, W., Newland, B., Yao, S., Wang, W., Chen, B., Madigan, N., Windebank, A. J., & Pandit, A. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.42 · Cited by 70
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 71
“Because of their episomal maintenance, the transferred genes are usually lost over time by dilution at cell division in actively dividing cells or by degradation in non-dividing cells [105].”
BackgroundJones, C. H., Chen, C., Jiang, M., Fang, L., Cheng, C., & Pfeifer, B. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300666s · Cited by 70
Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches
Mocellin, S., Rossi, C. R., Brandes, A. A., & Nitti, D. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.10.003 · Cited by 70
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
“Viral vectors have also been used to transduce a wide variety of tissues from liver, skeletal muscle, heart, brain, lung, pancreas, to tumors [109].”
BackgroundHighly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases
Zeng, M., Xu, Q., Zhou, D., Sigen, A., Alshehri, F., Lara‐Sáez, I., Zheng, Y., Li, M., & Wang, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113842 · Cited by 69
DNA Vaccines Approach: From Concepts to Applications
Pereira, V. B., Zurita-Turk, M., Saraiva, T. D. L., de Castro, C. P., Souza, B. M., Mancha-Agresti, P. D. C., Lima, F. A., Pfeiffer, V. N., de Azevedo, M. S. P., Rocha, C. S., et al. (2014) · World Journal of Vaccines · doi:10.4236/wjv.2014.42008 · Cited by 69
“Moreover, severe adverse effects were observed during two independent gene therapy trials, raising serious safety concerns about the use of viral vectors [88] [89].”
BackgroundCurrent and emerging factor VIII replacement products for hemophilia A
Cafuir, L. A., & Kempton, C. L. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717721458 · Cited by 69
Comprehensive Review on Silk at Nanoscale for Regenerative Medicine and Allied Applications
Mehrotra, S., Chouhan, D., Konwarh, R., Kumar, M., Jadi, P. K., & Mandal, B. B. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01560 · Cited by 69
Triboelectric nanogenerators for self-powered drug delivery
Li, X., Tat, T., & Chen, J. (2021) · Trends in Chemistry · doi:10.1016/j.trechm.2021.04.009 · Cited by 69
Salivary glands: novel target sites for gene therapeutics
Baum, B. J., Voutetakis, A., & Wang, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.10.003 · Cited by 69
Gene therapy imaging in patients for oncological applications
Peñuelas, I., Haberkorn, U., Yaghoubi, S. S., & Gambhir, S. S. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1928-3 · Cited by 69
“The induction of mutations due to integration of the transduced DNA into the host’s genome in non-target cells is another great concern [114, 115], and the better way to avoid it would be to obtain extremely specific vectors that are only able to transduce specific cells [116].”
BackgroundBioengineered nanotechnology for nucleic acid delivery
Zhang, Y., Luo, J., Gui, X., Zheng, Y., Schaar, E., Liu, G., & Shi, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.034 · Cited by 68
Nanotechnology in animal production—Upstream assessment of applications
Kuzma, J. (2010) · Livestock Science · doi:10.1016/j.livsci.2010.02.006 · Cited by 68
“Viral vectors in human gene therapy have been suspected in death and leukemia-like disorders (Thomas et al., 2003).”
BackgroundMairhofer, J., & Grabherr, R. M. (2008) · Molecular Biotechnology · doi:10.1007/s12033-008-9046-7 · Cited by 68
“The use of plasmid DNA (pDNA) appears safer compared to viral vectors [1, 2]; the ease of production allows the generation of quantities to address whole populations [3] and in the case of transient protein expression its use remains attractive due to the short time required ‘‘from bench to shelf,’’ as compared to, e.”
BackgroundAnti-angiogenic gene therapy in the treatment of malignant gliomas
Gatson, N. T., Chiocca, E. A., & Kaur, B. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.001 · Cited by 68
Tailoring highly branched poly(β-amino ester)s: a synthetic platform for epidermal gene therapy
Huang, J.-Y., Gao, Y., Cutlar, L., Ahern, J. O., Zhao, T., Lin, F., Zhou, D., McMahon, S., Greiser, U., Wang, W., et al. (2015) · Chemical Communications · doi:10.1039/c5cc02193f · Cited by 68
Xiao, T., Hou, W., Cao, X., Wen, S., Shen, M., & Shi, X. (2013) · Biomaterials Science · doi:10.1039/c3bm60138b · Cited by 68
Gene therapy for ischemic heart disease
Hinkel, R., Trenkwalder, T., & Kupatt, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.570749 · Cited by 68
“Even though recombinant AAVs mostly stay episomal non-specific integration may occur and can correlate with deletions or chromosomal rearrangements [18].”
BackgroundCurrent strategies for DNA therapy based on lipid nanocarriers
Pensado, A., Seijo, B., & Sánchez, A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.935337 · Cited by 68
“Indeed, concerns over their immunogenicity and toxicity have significantly impeded their clinical application [2].”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.